This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Interactions

Authoring team

  • the manufacturer recommends that reboxetine should be used with caution in patients prescribed medication that is metabolised by CYP3A4 e.g. antiarrhythmic drugs (1). Also reboxetine should not prescribed with drugs that may inhibit CYP3A4 e.g. azole antifungal drugs

  • should not be used concomitantly with monoamine oxidase inhibitors

  • there is a risk of postural hypotension in patients taking antihypertensive medication

Check the summary of product characteristics before prescribing this drug.

Reference:

  • Drug and Therapeutics Bulletin (1998), 36 (11), 82-4.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.